Hold onto your hats! Sanofi just made a bold move, scooping up Blueprint Medicines for a cool $9.5 billion. This deal is all about rare immunology — the kind of medicine that helps folks with super-rare conditions. Blueprint’s headliner is Ayvakit (avapritinib), the only FDA-approved treatment for advanced systemic mastocytosis, a rare blood disorder. Sanofi’s […]